Longyi Zeng

Prof. Dr. Longyi Zeng

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in The Lancet
Verified
Journal Article
Closed access
Jianping WengJianping Weng
Jianping Weng
YLYanbing Li
Yanbing Li
WXWen Xu
Wen Xu
LSLixin Shi
Lixin Shi
QZQiao Zhang
Qiao Zhang
HCHua Cheng
Hua Cheng

7 August 2015 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
RLRenyuan Li
Renyuan Li
WXWen Xu
Wen Xu
SLSihui Luo
Sihui Luo
HXHaixia Xu
Haixia Xu
GTGuoyu Tong
Guoyu Tong
Jianping WengJianping Weng
Jianping Weng

1 June 2015 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
MWMan-Man Wang
Man-Man Wang
SLShou Lin
Shou Lin
YCYanming Chen
Yanming Chen
JSJiong Shu
Jiong Shu
HLHong-Yun Lu
Hong-Yun Lu
PMPan-Wei Mu
Pan-Wei Mu
This study compared the effects on glycaemic variability and glucose control between saxagliptin and acarbose as add-on therapies for aged T2DM inadequately controlled with metformin alone. The results showed that compared with acarbose-metformin, saxagliptin-metformin was more effective in glucose control with similar glycaemic variability.

1 July 2018 in Cellular Signalling
Verified
Journal Article
Closed access
WZWen Zeng
Wen Zeng
JTJiansong Tang
Jiansong Tang
HLHaicheng Li
Haicheng Li
HXHaixia Xu
Haixia Xu
HLHongyun Lu
Hongyun Lu
LZLongyi Zeng
Longyi Zeng

1 July 2016 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
HLHongyun Lu
Hongyun Lu
XLXiaofeng Li
Xiaofeng Li
PMPanwei Mu
Panwei Mu
BQBaiying Qian
Baiying Qian
WJWei Jiang
Wei Jiang
LZLongyi Zeng
Longyi Zeng

1 January 2012 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
LZLongyi Zeng
Longyi Zeng
HLHongyun Lu
Hongyun Lu
HDHongrong Deng
Hongrong Deng
PMPanwei Mu
Panwei Mu
XLXiaofeng Li
Xiaofeng Li
MWManman Wang
Manman Wang
Aims: In newly diagnosed type 2 diabetes mellitus (T2DM) patients, short-term insulin therapy might improve β-cell function and glycemic control. This study aimed to compare the effects of basal insulin monotherapy with continuous subcutaneous insulin infusion (CSII) treatment. Methods: Fifty-nine cases of newly diagnosed T2DM patients with fasting plasma glucose of 9.0–16.7 mmol/L were recruited into this study. They were hospitalized and randomly assigned to a basal insulin monotherapy group ( n =27) or a CSII group ( n =32). Insulin dosage was titrated according to fasting capillary blood glucose levels, and treatment was stopped after 2 weeks. Intravenous glucose tolerance tests were performed, and blood glucose, insulin, C-peptide, and lipid profiles were measured before therapy and 2 days after therapy withdrawal. Results: Both treatments reduced fasting and postprandial blood glucose levels (after treatment vs. baseline, both P <0.05). Fasting glycemic control target was achieved in 52 cases (88.14%) with 2 weeks of insulin treatment, and there were no significant differences between the glargine and CSII groups ( P =0.059). The time to achieve fasting glycemic target in the CSII group was shorter than that in the glargine group ( P <0.01). Plasma lipid profiles such as triglycerides and total cholesterol also decreased significantly after the intervention. Overall β-cell function improved significantly after insulin intervention ( P 0.05). Conclusions: The effect of basal insulin monotherapy was similar to that of CSII, and thus basal insulin monotherapy might be a reasonable alternative to CSII for initial insulin therapy in newly diagnosed T2DM patients.